Current Challenges of Cancer Anti-angiogenic Therapy and the Promise of Nanotherapeutics.
Current Challenges of Cancer Anti-angiogenic Therapy and the Promise of Nanotherapeutics.
复制标题
癌症抗血管生成治疗的当前挑战和纳米治疗的前景。
作者：
Abdalla AME;Xiao L;Ullah MW;Yu M;Ouyang C;Yang G
随着对癌症治疗的兴趣日益增长，抗血管生成疗法已经受到相当大的关注，并且在几种类型的人类癌症中广泛施用。尽管如此，与细胞毒性药物相比，这种类型的治疗可能会诱导多种信号通路，并导致耐药、侵袭、转移和总生存期（OS）方面的结局更差。此外，存在限制将有前景的生物标志物转化为临床实践以监测抗血管生成治疗的效率的重要挑战。这些缺陷强调了迫切需要发现靶向多种血管生成因子的替代血管生成抑制剂或为当前抑制剂开发新的药物递送系统。纳米颗粒的巨大优势在于它们能够提供有效的途径，靶向生物系统并根据其独特的特征调节不同的生命过程。到目前为止，有限的研究已经解决了纳米颗粒在刺激（促血管生成）和抑制（抗血管生成）因子之间微妙平衡的正常化中的有效性。在这篇综述中，我们阐明了肿瘤血管及其微环境，并考虑了目前的抗血管生成和纳米治疗的方向。据我们所知，我们认为在了解可以控制新血管生长的抗血管生成剂（通常是少量金属，非金属分子或聚合物）方面做出了重要努力。
With growing interest in cancer therapeutics, anti-angiogenic therapy has received considerable attention and is widely administered in several types of human cancers. Nonetheless, this type of therapy may induce multiple signaling pathways compared with cytotoxics and lead to worse outcomes in terms of resistance, invasion, metastasis, and overall survival (OS). Moreover, there are important challenges that limit the translation of promising biomarkers into clinical practice to monitor the efficiency of anti-angiogenic therapy. These pitfalls emphasize the urgent need for discovering alternative angiogenic inhibitors that target multiple angiogenic factors or developing a new drug delivery system for the current inhibitors. The great advantages of nanoparticles are their ability to offer effective routes that target the biological system and regulate different vital processes based on their unique features. Limited studies so far have addressed the effectiveness of nanoparticles in the normalization of the delicate balance between stimulating (pro-angiogenic) and inhibiting (anti-angiogenic) factors. In this review, we shed light on tumor vessels and their microenvironment and consider the current directions of anti-angiogenic and nanotherapeutic treatments. To the best of our knowledge, we consider an important effort in the understanding of anti-angiogenic agents (often a small volume of metals, nonmetallic molecules, or polymers) that can control the growth of new vessels.
登录
查看更多内容
表皮生长因子受体抑制通过血管正常化调节微环境，从而提高化疗和放疗疗效。
影响因子：
3.7
作者：
Cerniglia, George J.;Pore, Nabendu;Tsai, Jeff H.;Schultz, Susan;Mick, Rosemarie;Choe, Regine;Xing, Xiaoman;Durduran, Turgut;Yodh, Arjun G.;Evans, Sydney M.;Koch, Cameron J.;Hahn, Stephen M.;Quon, Harry;Sehgal, Chandra M.;Lee, William M. F.;Maity, Amit
通讯作者：
Maity, Amit
影响因子：
9.7
作者：
Banerjee, Indranil;De, Kakali;Misra, Mridula
通讯作者：
Misra, Mridula
影响因子：
17.1
作者：
Chaudhuri, Padmaparna;Harfouche, Rania;Sengupta, Shiladitya
通讯作者：
Sengupta, Shiladitya
影响因子：
45.3
作者：
Bellon, JR;Come, SE;Recht, A
通讯作者：
Recht, A
DOI：
10.1038/nrc2442
发表时间：
2008-08
期刊：
Nature reviews. Cancer
影响因子：
--
作者：
通讯作者：
--